• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在缺乏Janus激酶2的情况下的红细胞生成:BCR-ABL在JAK2基因敲除的造血祖细胞中诱导红细胞形成。

Erythropoiesis in the absence of janus-kinase 2: BCR-ABL induces red cell formation in JAK2(-/-) hematopoietic progenitors.

作者信息

Ghaffari S, Kitidis C, Fleming M D, Neubauer H, Pfeffer K, Lodish H F

机构信息

Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, MA 02142, USA.

出版信息

Blood. 2001 Nov 15;98(10):2948-57. doi: 10.1182/blood.v98.10.2948.

DOI:10.1182/blood.v98.10.2948
PMID:11698276
Abstract

The receptor-associated protein tyrosine kinase janus-kinase 2 (JAK2) is essential for normal red cell development and for erythropoietin receptor (EpoR) signaling. JAK2(-/-) embryos are severely deficient in erythropoiesis and die at an early stage of development from fetal anemia. The binding of erythropoietin (Epo) to the EpoR triggers the activation of JAK2, the phosphorylation of the EpoR, and the initiation of the EpoR signaling cascade. In addition to Epo binding to its receptor, signaling pathways downstream of the EpoR can also be stimulated by the BCR-ABL oncoprotein. This study explored whether JAK2 is required for BCR-ABL-mediated stimulation of erythropoiesis. Here, it is shown that JAK2 is constitutively tyrosine phosphorylated in cultured and primary erythroid cells expressing BCR-ABL. However, BCR-ABL effectively supports normal erythroid proliferation, differentiation, and maturation in JAK2-deficient fetal liver cells. Using mutants of BCR-ABL, this study shows that certain signaling pathways activated by BCR-ABL segments distinct from its tyrosine kinase domain are essential for rescue of erythropoiesis in JAK2(-/-) progenitors. The consequences of these multiple signaling pathways for normal erythroid development are discussed.

摘要

受体相关蛋白酪氨酸激酶janus激酶2(JAK2)对于正常红细胞发育和促红细胞生成素受体(EpoR)信号传导至关重要。JAK2基因敲除(-/-)胚胎的红细胞生成严重不足,并因胎儿贫血在发育早期死亡。促红细胞生成素(Epo)与EpoR的结合会触发JAK2的激活、EpoR的磷酸化以及EpoR信号级联反应的启动。除了Epo与其受体结合外,EpoR下游的信号通路也可被BCR-ABL癌蛋白激活。本研究探讨了JAK2是否是BCR-ABL介导的红细胞生成刺激所必需的。在此研究中发现,在表达BCR-ABL的培养细胞和原代红系细胞中,JAK2持续发生酪氨酸磷酸化。然而,BCR-ABL能有效支持JAK2缺陷型胎儿肝细胞的正常红系增殖、分化和成熟。利用BCR-ABL突变体,本研究表明,由BCR-ABL中与其酪氨酸激酶结构域不同的片段激活的某些信号通路,对于挽救JAK2基因敲除(-/-)祖细胞中的红细胞生成至关重要。文中还讨论了这些多种信号通路对正常红系发育的影响。

相似文献

1
Erythropoiesis in the absence of janus-kinase 2: BCR-ABL induces red cell formation in JAK2(-/-) hematopoietic progenitors.在缺乏Janus激酶2的情况下的红细胞生成:BCR-ABL在JAK2基因敲除的造血祖细胞中诱导红细胞形成。
Blood. 2001 Nov 15;98(10):2948-57. doi: 10.1182/blood.v98.10.2948.
2
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.Lnk抑制红细胞生成以及Epo依赖的JAK2激活和下游信号通路。
Blood. 2005 Jun 15;105(12):4604-12. doi: 10.1182/blood-2004-10-4093. Epub 2005 Feb 10.
3
BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells.BCR-ABL和v-SRC酪氨酸激酶癌蛋白在促红细胞生成素受体缺陷的祖细胞中支持正常的红系发育。
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13186-90. doi: 10.1073/pnas.96.23.13186.
4
BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.BCR-ABL 而非 JAK2 V617F 通过诱导 p21CIP1/WAF1 抑制 Ras 信号通路从而抑制红细胞生成。
J Biol Chem. 2010 Oct 8;285(41):31774-82. doi: 10.1074/jbc.M110.118653. Epub 2010 Jul 27.
5
Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor.Vav的酪氨酸磷酸化诱导及Pim-1的表达与Jak2介导的来自促红细胞生成素受体的生长信号传导相关。
Blood. 1994 Dec 15;84(12):4135-41.
6
JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.JAK2 V617F通过激活Stat1和其他非红系信号通路,刺激促红细胞生成素依赖的红系祖细胞增殖并延缓其分化。
Exp Hematol. 2016 Nov;44(11):1044-1058.e5. doi: 10.1016/j.exphem.2016.07.010. Epub 2016 Jul 26.
7
HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.HLA-G通过JAK2和JAK2 V617F去磷酸化关闭促红细胞生成素受体信号传导:真性红细胞增多症的临床相关性
Leukemia. 2008 Mar;22(3):578-84. doi: 10.1038/sj.leu.2405050. Epub 2007 Dec 6.
8
AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation.AKT诱导JAK2缺陷型胎儿肝脏祖细胞的红细胞成熟,并且是促红细胞生成素(Epo)调节红细胞分化所必需的。
Blood. 2006 Mar 1;107(5):1888-91. doi: 10.1182/blood-2005-06-2304. Epub 2005 Oct 27.
9
Erythropoietin induces tyrosine phosphorylation of the interleukin-3 receptor beta subunit (betaIL3) and recruitment of Stat5 to possible Stat5-docking sites in betaIL3.促红细胞生成素诱导白细胞介素-3受体β亚基(βIL3)的酪氨酸磷酸化,并使Stat5募集至βIL3中可能的Stat5对接位点。
Blood. 1997 Jun 15;89(12):4327-36.
10
CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2.CIS3/SOCS-3通过结合促红细胞生成素(EPO)受体和JAK2来抑制促红细胞生成素(EPO)信号传导。
J Biol Chem. 2000 Sep 22;275(38):29338-47. doi: 10.1074/jbc.M003456200.

引用本文的文献

1
Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Upadacitinib for Induction Treatment of Refractory Crohn's Disease.强化粒细胞和单核细胞吸附性血液成分分离术联合乌帕替尼用于难治性克罗恩病的诱导治疗
J Clin Med Res. 2025 Apr;17(4):240-246. doi: 10.14740/jocmr6188. Epub 2025 Apr 5.
2
Efficacy and Safety of Upadacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction for Intractable Ulcerative Colitis.乌帕替尼联合强化粒细胞和单核细胞吸附性治疗作为难治性溃疡性结肠炎诱导治疗的疗效和安全性
J Clin Med Res. 2024 May;16(5):256-263. doi: 10.14740/jocmr5165. Epub 2024 May 29.
3
Upadacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis for Ulcerative Colitis Achieved Ulcer Healing for Pyoderma Gangrenosum.
乌帕替尼联合强化粒细胞和单核细胞吸附性血液成分去除术治疗溃疡性结肠炎实现了坏疽性脓皮病的溃疡愈合。
J Clin Med Res. 2023 Dec;15(10-11):446-455. doi: 10.14740/jocmr5005. Epub 2023 Nov 3.
4
Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.乌帕替尼相对于托法替尼对 JAK1 的优先抑制:来自 2 项 1 期临床试验的体外数据的暴露-反应分析及与托法替尼的比较。
J Clin Pharmacol. 2020 Feb;60(2):188-197. doi: 10.1002/jcph.1513. Epub 2019 Aug 25.
5
Intracellular Signaling Pathways Involved in Childhood Acute Lymphoblastic Leukemia; Molecular Targets.儿童急性淋巴细胞白血病相关的细胞内信号通路;分子靶点。
Indian J Hematol Blood Transfus. 2016 Jun;32(2):141-53. doi: 10.1007/s12288-015-0609-z. Epub 2015 Oct 20.
6
FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis.FOXO3-mTOR 代谢合作调节红细胞成熟和稳态。
Am J Hematol. 2014 Oct;89(10):954-63. doi: 10.1002/ajh.23786. Epub 2014 Jul 22.
7
α-1,6-Fucosyltransferase (FUT8) inhibits hemoglobin production during differentiation of murine and K562 human erythroleukemia cells.α-1,6-岩藻糖基转移酶 (FUT8) 在鼠和 K562 人红白血病细胞分化过程中抑制血红蛋白的产生。
J Biol Chem. 2013 Jun 7;288(23):16839-16847. doi: 10.1074/jbc.M113.459594. Epub 2013 Apr 22.
8
Myelofibrosis 2012: it's complicated.骨髓纤维化 2012:错综复杂。
Ther Adv Hematol. 2012 Jun;3(3):131-46. doi: 10.1177/2040620712437754.
9
JAK2 inhibition prevents innate immune responses and rescues animals from sepsis.JAK2 抑制可防止固有免疫反应,并使动物免受败血症的影响。
J Mol Med (Berl). 2010 Aug;88(8):851-9. doi: 10.1007/s00109-010-0628-z.
10
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.蛋白酶体抑制可导致白血病消退,并部分通过调节叉头框肿瘤抑制因子消除BCR-ABL诱导的细胞凋亡逃避。
Cancer Res. 2009 Aug 15;69(16):6546-55. doi: 10.1158/0008-5472.CAN-09-0605. Epub 2009 Aug 4.